Halofuginone-hydrobromide-RU-19110-hydrobromide-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEHalofuginone hydrobromideCat. No.: HY-N1584ACAS No.: 64924-67-0Synonyms: RU-19110 (hydrobromide)分式: CHBrClNO分量: 495.59作靶點(diǎn): DNA/RNA Synthesis; TGF-beta/Smad作通路: Cell Cycle/DNA Damage; Stem Cell/Wnt; TGF-beta/Smad儲(chǔ)存式: Powder -20C

2、3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (100.89 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.0178 mL 10.0890 mL 20.1780 mL5 mM 0.4036 mL 2.0178 mL 4.0356 mL10 mM 0.2018 mL 1.0089 mL 2.0178 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期

3、限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.04 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/

4、mL (5.04 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oil1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (5.04 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Halofuginone hydrobromide (RU-19110 hydrobromide)Febrifugine 的種低毒性衍物，可從 Dichroafebrifuga 中分離出來 1。Halofuginone 種 ATP 競(jìng)爭(zhēng)

5、性的脯氨酰-tRNA 合成酶 (prolyl-tRNA synthetase)抑制劑，Ki 為 18.3 nM 2。Halofuginone 通過抑制 TGF- 活性可減輕關(guān)節(jié)炎 3。IC50 & Target Ki: 18.30.5 nM (prolyl-tRNA synthetase) 2體外研究 Halofuginone competitively inhibits prolyl-tRNA synthetase by occupying both the prolineand tRNA-bindingpockets of prolyl-tRNA synthetase 1.The IC50

6、s of Halofuginone (1, 10, 100, 1000, 10000 nM; 48 hours) are 114.6 and 58.9 nM in KYSE70 andA549 cells, respectively.The IC50s of Halofuginone (1, 10, 100, 1000 nM; 24 hours) for NRF2 protein are 22.3 and 37.2 nM inKYSE70 and A549 cells, respectively. The IC50 of Halofuginone for global protein synt

7、hesis is 22.6 and 45.7nM in KYSE70 and A549 cells, respectively 1.Cell Viability Assay 1Cell Line: KYSE70 cells from human oesophageal cancer harbouring a mutation in the NRF2 geneand A549 cells harbouring theKEAP1 gene mutationConcentration: 1, 10, 100, 1000, 10000 nMIncubation Time: 48 hoursResult

8、: The IC50s were 114.6 and 58.9 nM in KYSE70 and A549 cells, respectively.Western Blot Analysis 1Cell Line: KYSE70 cells from human oesophageal cancer harbouring a mutation in the NRF2 geneand A549 cells harbouring theKEAP1 gene mutation.Concentration: 1, 10, 100, 1000 nMIncubation Time: 24 hoursRes

9、ult: The IC50s for NRF2 protein were 22.3 and 37.2 nM in KYSE70 and A549 cells,respectively.體內(nèi)研究Halofuginone (0.2, 0.5, 1 or 2.5 mg/kg; injected intraperitoneally every other day for 1 month) attenuatesprogression of OA in anterior cruciate ligament transection (ACLT) mice. Lower concentration (0.2

10、or 0.5mg/kg) has minimal effects on subchondral bone and higher concentration (2.5 mg/kg) induces proteoglycanloss in articular cartilage 3.Halofuginone (0.25 mg/kg; intraperitoneally injected; every day; 16 days) decreases NRF2 protein levels in2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEtumor

11、s. While the tumor volumes do not change substantially between treatments with the vehicle,Halofuginone (0.25 mg/kg, intraperitoneally injected, every day) or cisplatin alone. Combined treatment withHalofuginone and Cisplatin significantly suppresses the tumor volume compared to treatment withHalofu

12、ginone or cisplatin alone 1.Animal Model: 3-month-old male C57BL/6J (WT) mice 3Dosage: 0.2, 0.5, 1 or 2.5 mg/kgAdministration: Injected intraperitoneally every other day for 1 monthResult: Attenuated progression of OA in ACLT mice.Animal Model: Male nude mice (BALB/C nu/nu mice) (6-8-week) 1Dosage:

13、0.25 mg/kgAdministration: Intraperitoneally injected; every day; 16 daysResult: The combined treatment with Cisplatin significantly suppressed the tumor volume. NRF2protein levels in tumors were indeed decreased.REFERENCES1. Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer ce

14、lls by suppressing NRF2 accumulation. Free Radic BiolMed. 2017 Feb;103:236-247.2. Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.3. Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF- activity and H-type vessel formation in subchondral bone. AnnRheum Dis. 2016 Sep;7